Table 2.
Clinical parameters and SREBPs expression in low-risk complexity, high-risk complexity and non-CAD control participants
| Characteristic | CAD patients | Non-CAD Controls n = 178 |
P value | ||
|---|---|---|---|---|---|
| GROUP A1 n = 77 |
Group B 2 n = 141 |
P 3 | P 4 | ||
| Demographics | |||||
| Age (years) | 58.33 ± 9.28 | 59.32 ± 9.35 | 58.98 ± 9.32 | 0.617 | 0.114 |
| Male | 45 | 96 | 141 | ||
| Clinical parameters | |||||
| TC (mmol/L) | 3.94 ± 1.01 | 3.64 ± 1.06 | 4.81 ± 0.94 | < 0.001 | < 0.001 |
| TG (mmol/L) | 1.32(0.88, 2.03) | 1.15(0.69, 2.06) | 1.26(0.82, 1.48) | 0.004 | 0.335 |
| HDL-C (mmol/L) | 1.08 ± 0.26 | 0.97 ± 0.25 | 1.41 ± 0.33 | < 0.001 | < 0.001 |
| LDL-C (mmol/L) | 1.97 ± 0.68 | 1.87 ± 0.71 | 2.27 ± 0.59 | < 0.001 | < 0.001 |
| Apo-A1 (g/L) | 1.57 ± 0.26 | 1.43 ± 0.29 | 1.62 ± 0.21 | 0.157 | < 0.001 |
| Apo-B (g/L) | 0.82 ± 0.22 | 0.82 ± 0.25 | 0.91 ± 0.21 | 0.002 | < 0.001 |
| LP(a) (mg/L) | 102.8 ± 92.61 | 123.70 ± 110.20 | 78.20 ± 84.93 | 0.048 | < 0.001 |
| AST (IU/L) | 23.0(16.5, 29.0) | 23.00(18.00, 37.00) | 25.14(20.00, 29.17) | 0.314 | 0.488 |
| CK-MB (IU/L) | 16.66 ± 10.10 | 15.38 ± 10.27 | 8.43 ± 6.90 | < 0.001 | < 0.001 |
| LDH (IU/L) | 190.13 ± 47.62 | 195.52 ± 74.70 | 187.43 ± 42.60 | 0.655 | 0.783 |
| HBDH (IU/L) | 124.81 ± 37.79 | 130.14 ± 58.08 | 119.69 ± 30.05 | 0.250 | 0.050 |
| hs-CRP (mg/L) | 6.13(4.51, 8.27) | 8.05(4.81, 14.90) | 5.26(2.17, 5.71) | < 0.001 | < 0.001 |
| HCY (μmol/L) | 9.90(7.50,12.45) | 11.75(8.65, 13.68) | 11.30(8.90,12.50) | 0.190 | 0.007 |
| CysC (mg/L) | 0.59 ± 0.21 | 0.61 ± 0.22 | 0.59 ± 0.14 | 0.882 | 0.323 |
| GSP (mmol/L) | 2.70(2.43, 2.94) | 2.57(2.37, 2.86) | 2.61(2.46, 2.74) | 0.089 | 0.856 |
| SREBP-1 (fold change) | 0.85 ± 1.15 | 0.56 ± 1.12 | 1.00 ± 1.17 | 0.357 | 0.001 |
| SREBP-2 (fold change) | 1.12 ± 1.29 | 0.83 ± 1.39 | 1.00 ± 0.89 | 0.450 | 0.206 |
1 Group A, SYNTAX score of < 23; 2 Group B, SYNTAX score of ≥23; 3 Group A compare with non-CAD controls; 4 Group B compared with non-CAD controls